News Of The Day
|
Check Out The Blog Updated Daily;
HCV In The News News Of The Day DDW 2013 - May 18-21, 2013 - Orlando, FL Digestive Disease Week - The conference will showcase the latest advances in GI research, medicine and technology in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery View Media and DDW Updates EASL - News Updates continue May 18 NATAP - Summary EASL 2013 - New HCV DAAs on their way soon: what do the phase III studies tell us? Current and Future Therapies for Hepatitis C Virus Infection If the past is a harbinger of the future, therapy for HCV infection will probably continue to advance at a brisk pace. Many additional potent agents are in the clinical pipeline, and interferon-free regimens are likely to dominate the HCV therapeutic landscape within the next 5 years..... Hepatitis C in the United States Perspective Care for hepatitis C is evolving rapidly, with increasingly effective and better-tolerated antiviral therapies being evaluated and approved for use. It's clear, however, that not everyone who would qualify for therapy has been tested and identified, referred for appropriate care, and offered or given the best therapy available. Furthermore, currently used antiviral drugs - pegylated interferon and ribavirin "base" plus either telaprevir or boceprevir - can cost more than $70,000 for a full course of therapy. It is expected that the new oral antiviral agents will be just as expensive, at least in the short term. May 17 Organ donor cards hard to implement in China and China's unethical practice of organ harvesting To understand the importance of today's news from China to implement consent for organ transplants or donor cards, the public may need some background on China's unethical practice of organ harvesting from imprisoned Falun Gong practitioners As Hepatitis C Spreads, Scotland Steps In Minn. DOH recommend one-time Hepatitis-C shots for Baby Boomers Stop paid blood donor clinics in Toronto, victims say May 15 Watch - Best of the EASL 2013 on hepatitis C - webcast with Dr Andrew Muir Hepatitis C Therapy Update 2013-What About Interferon-free Regimens? Interferon-free regimens are widely being tested in clinical trials with encouraging results. The following selected trials demonstrate how rapidly progress is being made. Beginning in 2010, studies demonstrated the potential for antiviral efficacy of an all-oral regimen using combinations of drugs with different targets. Report highlights major failings in UK response to hepatitis C The UK needs to “be doing so much more” in response to hepatitis C, according to a new report. Supported by a consortium of leading hepatitis C charities BLOG: One in four Massachusetts physicians received gifts, industry payments According to a recent report in The New England Journal of Medicine, one in four physicians in Massachusetts received at least one gift or payment from pharmaceutical or medical device companies valued at $50 or more since the commonwealth began tracking these payments in July 2010 . May 14 Is There a Future for Milk Thistle In HCV? Research, a few studies which offer a better understanding of the popular supplement, including the possible benefits. May 13 U.S. FDA grants priority review to Simeprevir (TMC435) for combination treatment of genotype 1 chronic hepatitis C Janssen Research & Development, LLC (Janssen) announced today that the FDA has granted Priority Review to the New Drug Application (NDA) for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease. Drug-Induced Liver Injury in Elderly Patients Differs From Younger Patients Spring Hepatitis Newsletters- Waiting for Approval of Drugs... What About Herbal Supplements? May 6 AbbVie's Investigational Hepatitis C Virus Regimen Gets Breakthrough-Therapy Designation AbbVie’s investigational direct-acting antiviral (DAA) combination regimen with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA). ABT-450, Enanta’s lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, is one of three DAAs in the regimen. Boceprevir/peginterferon/ribavirin effective, safe in chronic HCV patients with compensated cirrhosis May 2 Gilead Sofosbuvir and ledipasvir: Plans to initiate a third Phase 3 clinical trial with and without ribavirin Surveyed Gastroenterologists Agree - Gilead's interferon-free regimen has Advantages Over Current Hepatitis C Therapies EASL 2013 - Internet Symposium: Watch Advances in Chronic Hepatitis C Management and Treatment April 30 Hepatitis C: Sofosbuvir and Daclatasvir - Off Label Use? Cost will limit uptake of off-label Gilead/Bristol-Myers Squibb Hep C combo, despite best-in-class data With different assets in the HCV development space offering various mechanisms of action, mechanism diversity and potency, one suggestion is that once individual components become available, physicians will prescribe them together in an off-label capacity. Hepatitis C - Will physicians go off label, and prescribe Sofosbuvir and Daclatasvir? The articles emphasize the highly successful HCV drug regimen; hinting at an off label use after both drugs are FDA approved, the backstory and the results presented Saturday at the liver conference. Vertex posts loss, raises cystic fibrosis drug sales view Reuters) - Vertex Pharmaceuticals Inc on Tuesday reported a fourth successive quarterly loss on plunging sales of its hepatitis C drug, Incivek, but the biotechnology company raised its 2013 forecast by $20 million for sales of its cystic fibrosis drug that has become the focus for investors. April 29 Drug Trio Helps Treat HCV After Transplant AMSTERDAM -- Three-drug therapy appears to help liver transplant patients whose hepatitis C (HCV) recurs, a researcher said here Hemoglobin May Be Toxic for Diseased Liver 4/29/2013 AMSTERDAM -- High levels of hemoglobin may be dangerous in patients with non-alcoholic fatty liver disease (NAFLD), with bleeding a potential remedy, researchers said here. EASL 2013: 'Quad' HCV Tx Works but No More Trials Planned AMSTERDAM – A four-drug regimen was effective in hard-to-treat hepatitis C (HCV) patients who had previously failed therapy, a researcher said here, but the drug combination is not being further developed. April 28 Transgene: Promising Final Data from the Phase 2 HCVac Trial of TG4040 Presented at EASL 2013 EASL 2013 Highlights - CCO's independent conference coverage Combining ledipasvir with sofosbuvir/ribavirin yielded SVR12 rates of 100% in both treatment-naive patients and previous null responders, lending further support to ongoing development of the sofosbuvir/ledipasvir fixed-dose combination tablet.... CCO's independent conference coverage of the 2013 Annual Meeting of the European Association for the Study of the Liver includes 2 CME-certified slidesets with faculty analysis and downloadable slidesets that focuses on key issues highlighted at the conference. EASL: Liver Imaging Tests Vie to Replace Biopsy Although biopsy remains the gold standard for diagnosing liver fibrosis, imaging tests increasingly appear to be a viable way to garner equivalent information with less patient discomfort and risk, researchers said here Hepatitis C: Closing in on its viral origins The virus behind Hepatitis C has been the target of virologists, epidemiologists and geneticists for years, in a bid to find out the animal host from which it likely came. But Prof Jonathan Ball, a virologist at the University of Nottingham, UK, says early indications that bats are the culprit may yet be proven wrong. Attention Baby Boomers: Get Screened for Hepatitis C If you were born during 1945-1965, talk to your doctor about getting tested for hepatitis C. Baby boomers are five times more likely than other adults to be infected. In fact, 75 percent of adults with hepatitis C were born during these years. April 26 EASL- Watch: ALCOHOL'S DEADLY IMPACT EASL: Anemia Top Side Effect of HCV Antivirals EASL - Interferon-free, triple-DAA regimen safe, effective for chronic HCV EASL: Watch HEPATITIS C - NEW DAA's READY FOR PRIME TIME EASL: Watch - HEPATITIS C - EXISTING TREATMENTS EASL: Direct-acting antivirals now ready for prime time with promising alternatives on the way New Drug Stimulates Immune System to Kill Infected Cells in Animal Model of Hepatitis B Infection New antiviral drugs clear Hepatitis C in patients without treatment options EASL: INCIVO® Receives Positive Opinion from(CHMP) for Twice Daily Dosing for Geno1 April 25 Sunshine Hormone, Vitamin D, May Offer Hope for Treating Liver Fibrosis Sofosbuvir: the final nail in the coffin for hepatitis C? Commentary Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Gene variants linked to steatosis, fibrosis, steatohepatitis April 21 New In Multimedia Professor Colombo talks candidly about our understanding of hepatocellular carcinoma. Hepatitis C Management - Professor Jean-Michel Pawlotsky When Standard Liver Cancer Treatment Doesn't Work Or Isn't Possible, New Ablation Technique Holds Promise Liver Cancers Armed With Many Strategies For Evading Immune Response Dozens of Oklahoma Dentist's Patients Positive for Hepatitis Does HBV Suppression with Entecavir Affect Clinical Outcomes? April 16 Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV Danoprevir:Roche, Ascletis to develop & commercialise danoprevir in China for treatment of hepatitis C FDA Approves FibroScan for Noninvasive Liver Diagnosis A painless alternative to liver biopsy for evaluating the stage of liver fibrosis. April 12 AASLD - New Hepatology Podcasts Sexual Transmission of Hepatitis C Vitamin A Deficiency and Hepatitis C Review: NS5A Inhibitors in the Treatment of Hepatitis NS5A inhibitors have pan‐genotypic activity, i.e. they suppress replication of all HCV genotypes, but their antiviral effectivenesses against genotypes other than 1 may vary from one molecule to another Treatment of hepatitis C virus infection in the future Two direct-acting antivirals (DAAs) against hepatitis C virus (HCV): telaprevir and boceprevir, are now available in combination with peginterferon plus ribavirin for the treatment of chronic hepatitis C infection. Although these drugs are potent inhibitors of HCV replication, they occasionally result in severe adverse events. In the present clinical trials, in their stead, several second-generation DAAs are being investigated. Most of them are being viewed with high expectations, but they also require the combination with peginterferon plus ribavirin. In the near future, we might be using all-oral DAAs and interferon-free regimens for the treatment of HCV-infected patients, and these would be potent inhibitors of HCV and have less adverse events. Hepatitis C Virus Infection: Looking for Interferon Free Regimens Recent developments of new drugs' combinations are changing the treatment paradigm in hepatitis C virus infection. Due to the side effect profile of pegylated interferons, interferon-sparing regimens have become the main target in chronic hepatitis C treatment research. Recent proofs of concept studies have suggested that cure of chronic hepatitis C can be achieved without interferon. The purpose of this paper is to provide an overview of the clinical results recently reported for the treatment of hepatitis C virus infection with interferon-free regimens, focusing on the most promising new compounds and combinations. Review Article: The Treatment of Genotype 1 Chronic Hepatitis C Virus Infection in Liver Transplant Candidates and Recipients April 8 Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir (GS-7977) for the Treatment of Hepatitis C -- Sofosbuvir Would Form Basis of First All-Oral Regimen for HCV Genotype 2 and 3 Patients, and Interferon-Sparing Regimen for Genotype 1 Patients -- April 7 Sofosbuvir/Ledipasvir -An ‘apocalypse moment’ for HCV? Daclatasvir/asunaprevir effective in difficult-to-treat HCV populations April 5 VX-135/daclatasvir: Vertex signs agreement with Bristol-Myers for all-oral midstage studies for hepatitis C treatments Vertex Pharmaceuticals Inc. (VRTX) entered a nonexclusive agreement with Bristol-Myers Squibb Co. (BMY) to conduct midstage studies for hepatitis C treatments, its latest collaboration as part of its push to develop treatments for the liver disease. The Phase 2 studies are for once-daily all-oral treatment regimens containing Vertex's nucleotide analogue hepatitis C virus polymerase inhibitor VX-135 and Bristol-Myers Squibb's NS5A replication complex inhibitor daclatasvir. As part of the agreement, Vertex plans to conduct two Phase 2 studies of the combination, including an initial study in treatment-naive people with genotype 1 hepatitis C virus, planned for the second quarter. Vertex plans to begin a subsequent study in treatment-naive people infected with genotype 1, 2 or 3 hepatitis C virus, including those with cirrhosis, in the second half, pending data from the initial study. Learning the basics about hepatitis C Hepatitis C Viral Load Fluctuates Without Treatment Six Ways to Help Your Liver Most liver disease in Canada (and likely the US) is caused by food abuse causing obesity and not by alcohol abuse. New 3D Imaging Gives New Hope to Liver Ultrasounds Reports Matrix Ultrasound April 2 Miravirsen safe, effective among patients with chronic HCV Patients with chronic hepatitis C genotype 1 treated with miravirsen experienced dose-dependent reductions in HCV RNA compared with placebo recipients in a recent study. Mortality among British Columbians testing for hepatitis C antibody These findings confirm that individuals who test anti-HCV positive have increased mortality related to progressive liver disease, and that a substantial proportion of the mortality is attributable to drug use and risk behaviours/activities associated with HCV acquisition. View provisional PDF. Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection The study investigated the use of the ChronVac-C DNA vaccine administered with Inovio's MedPulserTM-DDS electroporation device followed by a drug regimen (ribavirin + PEG-interferon-a) in chronic HCV positive subjects. These initial results do not show a statistically significant difference so far between treatment outcomes of the vaccinated and non-vaccinated groups. The vaccinated group did display an excellent safety profile. Oklahoma Warns 7000 Dental Patients of HIV, Hepatitis Risk Some 7000 people may have been exposed to HIV and other infectious diseases at an Oklahoma dental practice where improper sterilization procedures and rusty surgical tools were discovered. HCV coinfection not predictive of kidney disease in liver transplant recipients with HIV HCV "One-Shot-Cure" ddRNAi Therapy Study Starting Arthritis and Rash What musculoskeletal symptoms may accompany hepatitis C (HCV) infection? Updates on the website 2013-HCV Abstract Corner Hepatitis C Full Text Articles Publications @ HCV Advocate HCV Advocate Newsletter April 1, 2013 Click Here Type 2 Diabetes and Insulin Resistance in People with HCV: NEW!! Stigma and Hepatitis C A Guide to Coping with Depression and Hepatitis C Mar 29 Micromanaging Hepatitis C Virus Although protease inhibitors have greatly enhanced the sustained viral response rate, these inhibitors are active against only the dominant viral genotype found in North America and Europe (genotype 1), and about a third of patients with genotype 1 infection do not have sustained viral repression. Simeprevir (TMC435) - Janssen Submits New Drug Application to U.S. FDA Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C -- Filing Based on Phase 3 Data in Treatment-Naïve and Treatment-Experienced Patients with Compensated Liver Disease -- Mar 28 Watch - Miravirsen: First microRNA-targeted drug effective for hepatitis C Miravirsen, the first microRNA-targeted drug to enter human clinical trials, successfully reduced hepatitis C (HCV) RNA levels in patients with chronic HCV infection in a phase 2a trial, according to results published March 27 in the New England Journal of Medicine Mar 27 Miravirsen- Hepatitis C drug goes after patients’ RNA New research suggests that the drug, miravirsen, could potentially be part of a drug "cocktail" that manages the hepatitis C virus in much the same way as similar combinations have transformed HIV/AIDS from a death sentence into a chronic, manageable condition. Miravirsen suppresses molecules the hepatitis C virus needs to reproduce. Treating Hepatitis C: Are Children the Same as Adults? Editorial Sofosbuvir (GS-7977) Updates-Sofosbuvir combination shows promise in non-cirrhotic, treatment-naive HCV Data from a phase 2 trial suggest that adding 12 weeks of sofosbuvir to peginterferon alfa-2a and ribavirin may be beneficial in non-cirrhotic, treatment-naive patients with genotypes 1, 2 and 3 hepatitis C virus infection. Watch Dr. Joe Galati - Calculating the MELD Score and How it Works Mar 26 Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients Gilead Sciences, Inc. (Nasdaq: GILD) today provided an update on ION-1, a Phase 3 clinical trial evaluating a once-daily fixed-dose combination of the nucleotide sofosbuvir and the NS5A inhibitor ledipasvir with and without ribavirin (RBV) for 12 or 24 weeks among treatment-naïve genotype 1 patients with hepatitis C virus (HCV) infection Hyperpigmentation common adverse event of interferon-based chronic HCV therapy More than 20% of patients with chronic hepatitis C treated with interferon developed hyperpigmentation as a side effect of therapy in a recent study Hepatitis C- Interferon free regimens for the “difficult-to-treat”: Are we there? In this issue of the Journal of Hepatology, Suzuki et al. [4] evaluated the efficacy of dual therapy with asunaprevir and daclatasvir in 43 subjects infected with genotype 1b considered poor candidates for current treatment for hepatitis C (21 null responders and 22 ineligible or intolerant to interferon-based therapy). Patients with HCV may deliberately skip early treatment doses when feeling well Medication nonadherence during the first 24 weeks of treatment for chronic hepatitis C was often deliberate and attributed to feeling well, as opposed to forgetfulness or other factors, in a recent study GS7977+Peg/Rbv Gt1/4/5/6 ATOMIC Study The Lancet Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase. We assessed the safety and efficacy of sofosbuvir in combination with pegylated interferon alfa-2a (peginterferon) and ribavirin in non-cirrhotic treatment-naive, patients with HCV. View here Mar 13 Awareness of HCV infection lowers health-related quality of life Patients with chronic hepatitis C who were aware of their infection reported reduced quality of life compared with infected patients who were unaware, independent of factors attributable to the illness, in a recent study. The Story Behind "It's Nothing Personal" by Kate O'Reilley Dr. Sherry Gorman, who writes under the pen name Kate O'Reilley, discusses the hepatitis C outbreak at Rose Medical Center in 2008-2009. Hepatitis C - Presidio Collaboration with Boehringer Ingelheim for interferon-free Phase IIa clinical trial The Parties to Initiate a Phase IIa Trial of an All-Oral Combination of Presidio's HCV NS5A inhibitor (PPI-668) with Faldaprevir (BI201335) and BI207127 for the Treatment of Patients with Hepatitis C BioLineRx Receives Approval from French Regulatory Authorities to Commence a Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C BioLineRx Receives Approval from French Regulatory Authorities to Commence a Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C Mar 12 Do Futility Rules for HCV Triple Therapy Work? BiolineRX in advanced talks on hepatitis C drug development deal process. Early treatment for depression after liver transplantation linked to better survival Molecular Switch Discovered That Turns On Self-Renewal Of Liver Damage Faldaprevir ups interferon response in HIV/HCV co-infection NY aims to prevent unsafe injections - UPI.com Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner Hep C Bull March Newsletter: Should I Be Treated? Mar 7 Pfizer Stops Developing Hepatitis C Drug, Cites Strategic Review Mar 6 Interferon-free regimen cures 100% of hard-to-treat hepatitis C Recruiting Phase 2 Trial: Sofosbuvir(GS-7977) Interferon Sparing Roche wins FDA nod for hep C diagnostic Roche has secured the FDA's blessing for a new viral load hepatitis C test, designed to gauge a patient's response to treatment by identifying the virus' RNA levels. Veterans Affairs in forefront for hepatitis C treatment On most Thursdays, a small group of patients assembles at the VA hospital in West Haven because they share a common disease -- hepatitis C – and a common treatment -- a protocol of new antiviral drugs. First-ever drop in US sales of "traditional" drugs The decline, which is reported for spending by the US commercially-insured population last year, was offset by an 18.4% increase in spending by this group on specialty medications to treat more complex diseases such as rheumatoid arthritis, cancer and hepatitis C, according to the latest annual Drug Trend Report published by pharmacy benefit manager (PBM) Express Scripts. Mar 5 CROI: 20th Conference on Retroviruses and Opportunistic Infections All-Oral Regimens Work in HCV Updated 2013/HCV Multimedia Videos Podcasts Investment Commentary The Perfect Cure for Hepatitis C? Gilead-Medivir Hepatitis C Drug Clears Virus in Patients Infographic: Conversations from the Hepatitis C Exam Room French studies report real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection Mar 4 New Frontiers in Hepatitis C Virus Treatment Medivir:Simeprevir (TMC435) and Sofosbuvir (GS-7977) interim results from a phase IIa study Ledipasvir (GS-5885), Extra Drug Hikes HCV Regimen's Efficacy Liver stem cell therapy ‘on its way’ Mar 1 Skin can show first signs of some internal diseases HIV/Aging/Viral Infections: HCV Leading Cause of Death in HIV? Preoperative acute renal failure, renal replacement therapy increased liver transplant mortality risk Liver transplant recipients with preoperative acute renal failure who received renal replacement therapy were at greater risk for death than patients with preoperative acute-on-chronic renal failure in a recent study... Watch: Hepatitis C Management - Professor Mark Sulkowski 2013 : HCV News Digest |
EASL 2013 The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), will take place April 24 to 28 in Amsterdam, EASL Links Blog- News Updates Tips For Viewing Hepatitis C Abstracts EASL Website EASL Abstract Search Click here for a downloadable PDF version of the Abstract Book. EASL 2013 - Internet Symposium: Watch Advances in Chronic Hepatitis C Management and Treatment Quick Links - New Data- Hepatitis C Investigational Drugs AbbVie is a new, independent biopharmaceutical company composed of Abbott’s former proprietary pharmaceutical business ABT-267, ABT-333-non- nucleoside, ABT-450/r r = ritonavir May 6 Update AbbVie's Investigational Hepatitis C Virus Regimen Gets Breakthrough-Therapy Designation Achillion ACH-3102 Sovaprevir (ACH-3102) Boehringer Ingelheim Faldaprevir/ (BI 201335), Bristol-Myers Squibb Daclatasvir/asunaprevir/BMS-791325, Gilead Sofosbuvir (GS-7977) Ledipasvir (GS-5885) Idenix IDX719 Janssen Simeprevir (TMC435) Merck MK-5172 Daclatasvir MK-5172 and Daclatasvir MK-5172 and Daclatasvir-Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Victrelis Vertex ALS-2200 (VX-135) Incivek EASL - News Updates A Few Quick Links - News Updates News/Incivek (Telaprevir) News/Victrelis (Boceprevir) HCV Triple-therapy Side Effects Side Effects- Exploratory Interferon Free Therapies Interferon Free Combinations Sofosbuvir (GS-7977 and PSI-7977) News/Fibrosis News/Cirrhosis News/Transplant News/Liver Cancer Of Interest Lucinda K. Porter, RN Personal Experience - Starting 12 weeks of sofosbuvir, GS-5885, and ribavirin Coming in September 2013 A second book authored by Lucinda K. Porter, RN Hepatitis C Treatment One Step at a Time: Inspirational Readings and Practical Tips for Successful Hepatitis C Treatment First Book FREE FROM HEPATITIS C Telaprevir and Boceprevir Pocket Guide For UsingTelaprevir and Boceprevir Telaprevir/INCIVEK Prescribing Information for INCIVEK including the Medication Guide. Boceprevir/Victrelis Prescribing Information and Medication Guide Patient Assistance Programs INCIVEK/Telaprevir and VICTRELIS (Boceprevir) Patient Assistance Program Hepatitis C Pipeline Feb 20 2013- EASL-Burden of Liver Disease in Europe: Looks at leading causes of cirrhosis and primary liver cancer in Europe Need To Talk To Someone ? Help is available, recently "Project Inform" announced the launch of a new national helpline, 877-HELP-4-HEP (877-435-7443), run by and for people affected by hepatitis C. The helpline operates Monday through Friday 9am to 7pm EST. To learn more, visit www.help4hep.org email info@help4hep.org. New ALF Website The Hepatitis C: Diagnosis, Treatment, Support website 1-800-GOLIVER (1-800-465-4837) In addition, questions sent on e-mail to info@liverfoundation.org will be promptly answered. Hepatitis C Newsletters
HCV Advocate Newsletter The HCV Advocate newsletter is a valuable resource designed to provide the hepatitis C community with monthly updates on events, clinical research, and education HBV Advocate HBV Journal Review HepCBC Online monthly newsletter GI & Hepatology News is the official newspaper of the AGA Institute and provides the gastroenterologist with timely and relevant news and commentary about clinical developments and about the impact of health-care policy. The newspaper is led by an internationally renowned board of editors. Hep Magazine Newsletter Signup for Hep's email newsletter and keep with the latest info to help keep your liver healthy. http://lists.smartandstrong.com/?p=subscribe&id=13 Hepatitis C Victoria publishes two regular e-newsletters: Liver Spot, for people interested in general hepatitis news and views, and Viral Lowdown, for people working in and around the field of hepatitis C, as well as an electronic version of Good Liver, our quarterly magazine.You can sign up for any of these HERE. Hepatitis C Trust Newsletter Published every spring and winter. CAP Hepatitis C Literature Review Monthly Pubmed Review of the most relevant research on hepatitis C. Mailing Lists Subscribe to the NATAP HCV Mailing List email: nataphcv-request@natap.org *with a subject line of subscribe Learn more here HEPC-List The list continues to be a great source of support/information and can be joined by clicking here Magazine & Books Free from Hepatitis C:Your Complete Guide to Healing Hepatitis C Lucinda K. Porter, RN, author of Free from Hepatitis C, is a hepatitis C patient, nurse and recognized expert in the hepatitis C field. Lucinda was a clinical research nurse at Stanford University Medical Center’s Hepatology division. In 1998, she co-founded the Redwood City Hepatitis C Support Group. She has been a guest speaker, educator and consultant, particularly on the subject of hepatitis C. Lucinda is actively engaged in community awareness activities focusing on issues surrounding viral hepatitis. Learn More Here Hepatitis C No Longer a Lifelong Illness Leading hepatologist and hepatitis C expert Gregory Everson, M.D. provides state-of-the-science information in "Curing Hepatitis C" -- a new book that outlines the latest treatment protocols that offer the outcome of complete cure from this disease Hepatitis C Choices Free Online Book Important link if you are considering the new therapies. Be sure to talk with your doctor about all of your other medications prior to taking any prescription. Hep C Magazine Hepatitis NSW publishes two magazines: The Hep Review: is a 60 page magazine that comes out every three months, containing news, info, opinion, research and feature articles about hepatitis. Transmission Magazine: is a 16 page magazine that comes out every three months and is targeted at people affected by hep C or at risk of contracting it, and who prefer less text and more artwork. We strive to provide high quality magazines and content developed by us is produced according to our resources development guidelines. Where relevant, we provide author and source details. Each magazine is produced under the guidance of editorial committees made up of people from the hepatitis and related sectors, and people recruited for their experience in journalism and desktop publishing. Both our magazines aim to provide you with up-to-date information. They also give you the opportunity to provide input through telling your story, suggesting ideas for the articles that we write and helping with production (proofreading, mailouts, etc.) In this part of our website you will find: Hep Review magazine Hep Review index Hep Review promo campaign Transmission Magazine Email Alert FDA Hepatitis List Serve This e-mail list provides updates on safety and regulatory issues related to hepatitis B and C products (labeling changes, safety warnings, product approvals). Intended for patients, industry, academia, government agencies, and other interested parties. To sign up, click on link above. New Resource New Digital Liver Disease Journal - "Clinical Liver Disease" This journal is an official digital educational resource from the American Association for the Study of Liver Diseases. Visitors are able to view videos, full data, and download files in either HTML or PDF formats Hepatitis C Support Forums HCV Support HEPCnet Forums Med Help HepC Nomads Forum Hepatitis C Kids Support Forum Daily Strength Hepatitis C Support Hepatitis Central Hep C Friends Cirrhosis/ESLD Support The Liver Failure Support Group Transplant buddies |